Tag: Nabil Shabshab

GOLETA, Cailf. – Two major factors contributed to Inogen’s 13.2% increase in revenue in the third quarter: The company remediated “the significant portion of its backlog,” and it made “excellent progress” with its prescriber strategy, says President and CEO Nabil Shabshab.    Shabshab declined to detail the size of the backlog of orders in its domestic business-to-business channel, but Inogen recorded $42.5 million in sales for the channel in the third...

GOLETA, Calif. – Inogen has reported total revenue of $105.4 million for the third quarter of 2022, a 13.2% increase compared to the same period last year.  Revenue increased primarily due to higher domestic business-to-business sales, as well as continued strength in the rental channel, partially offset by lower international business-to-business and direct-to-consumer sales  “I am pleased with the progress the team has made on our transformational journey,” said...

GOLETA, Calif. – Supply chain challenges, as well as a temporary shutdown at facilities in Texas and California earlier this year, forced Inogen to prioritize available supply in the first quarter of 2022 to its domestic direct-to-consumer and rental channels, contributing to an 83.4% drop in revenues for its business-to-business channel.  “As of early May, we have started shipments to our domestic B2B channel in order to alleviate some of the backlog in our system,”...

GOLETA, Calif. – Inogen reported revenue of $76.4 million for the fourth quarter of 2021, an increase of 3.3% over the same period in 2020, driven by a 23.3% in domestic direct-to-consumer sales to $33 million.  Domestic business-to-business sales in the fourth quarter of 2021 decreased 57.6% to $10.3 million compared to $24.2 million in the fourth quarter of 2020, primarily due to the supply chain constraints that limited product availability in this channel.  Rental revenue...

GOLETA, Calif. – Inogen says its revenues are expected to increase for the fourth quarter of 2021, but a chip shortage has forced the company to temporarily suspend manufacturing operations at its Texas and California locations.  Inogen doesn’t expect to furlough any employees as a result of the suspension, as the company currently anticipates restarting manufacturing at all locations around mid- to late February 2022 based on the information available to date.  For the...

GOLETA, Calif. – Demand is high, but with supply restricted, Inogen is prioritizing POC orders from its direct-to-consumer channel.  That meant it was unable to fulfill some orders from other channels, particularly its domestic business-to-business channel, which saw sales of $22.8 million in the third quarter, down 1.1% from the same period last year.  "Due to supply chain constraints and in an effort to optimize financial results, we intentionally focused our available capacity...

GOLETA, Calif. – Inogen has named Stanislav Glezer, M.D., to the role of CTO responsible for R&D and engineering, medical affairs and regulatory affairs. Glezer, who joined Inogen in June, will remain an executive vice president of the company. He has more than 27 years of experience and has held leadership roles at a variety of medical technology and biotechnology firms, including Becton, Dickinson and Company, Adocia S.A., Novo Nordisk, Inc., and Sanofi S.A. “Since joining Inogen...

GOLETA, Cailf. – Inogen saw a nice boost in revenue in the second quarter, thanks to increasing consumer confidence and ambulation, but the company expects supply chain constraints to inhibit its ability to meet demand in the second half of 2021.  The company expects total revenue for the second half to be lower than the first half of the year, and it expects net losses for the third and fourth quarters, as well as for the full year.  “We continue to see strong consumer...

GOLETA, Calif. – Inogen reported total revenues of $86.9 million for the first quarter of 2021, a 1.8% decrease from the same period last year, primarily due to the impacts of the COVID-19 pandemic, the company says.  It reported a net loss of $732,000 vs. a net loss of $1.59 million.  “While the COVID-19 pandemic continued to have an impact on our business in the first quarter of 2021, we saw sequential growth in all four channels, and sequential growth of 17.5%...

GOLETA, Calif. – Inogen reported a 17.9% increase in sales of portable oxygen concentrators to HME providers in the fourth quarter of 2020, a sign of just how much the pandemic is straining the supply of stationary oxygen concentrators, a more common therapy for COVID-19 patients.  That’s compared to a 25.2% decrease in direct-to-consumer sales for the quarter.  “Traditionally, these patients are treated...